Protocol No.: V503-003-00-0255: "A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillornavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year Old Men and 16- to 26-Year Old Women"

Project: Other project

StatusFinished
Effective start/end date1/3/131/2/15

Funding

  • Merck Sharp & Dohme Corporation: $127,203.80